Menu Search
Equities

Halozyme Therapeutics Inc

RV7:FRA

Halozyme Therapeutics Inc

Actions
  • Price (EUR)53.08
  • Today's Change-3.10 / -5.52%
  • Shares traded150.00
  • 1 Year change+43.34%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Halozyme Therapeutics Inc grew revenues 25.62% from 660.12m to 829.25m while net income improved 39.31% from 202.13m to 281.59m.
Gross margin79.95%
Net profit margin38.62%
Operating margin46.04%
Return on assets17.85%
Return on equity153.16%
Return on investment19.11%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Halozyme Therapeutics Inc fell by 116.33m. However, the company earned 388.57m from its operations for a Cash Flow Margin of 46.86%. In addition the company used 96.91m on investing activities and also paid 407.99m in financing cash flows.
Cash flow per share3.20
Price/Cash flow per share18.83
Book value per share2.29
Tangible book value per share-4.46
More ▼

Balance sheet in USDView more

Halozyme Therapeutics Inc has a Debt to Total Capital ratio of 83.85%, a lower figure than the previous year's 990.51%.
Current ratio7.41
Quick ratio6.21
Total debt/total equity5.19
Total debt/total capital0.8385
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.